Rösler A, Weshler N, Leiberman E, Hochberg Z, Weidenfeld J, Sack J, Chemke J
Department of Endocrinology and Metabolism, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
J Clin Endocrinol Metab. 1988 Apr;66(4):830-8. doi: 10.1210/jcem-66-4-830.
Hormonal measurements in maternal urine and amniotic fluid (AF) during pregnancy and/or at delivery correctly predicted the postnatal diagnosis of 11 beta-hydroxylase deficiency congenital adrenal hyperplasia (11 beta-OH deficiency CAH) in 7 fetuses at risk. In the 4 affected ones, maternal urinary tetrahydro-11-deoxycortisol (THS) excretion was high during the first trimester [0.3-2.2 mg/day (1.1-7.7 mumol/day)] and rose further during the third trimester [0.5-3.5 mg/day (1.8-12.3 mumol/day)] compared to urinary THS excretion in 20 normal pregnancies of the same gestational age (P less than 0.01). In 1 mother, dexamethasone administration (2 mg/day for 72 h) greatly reduced urinary THS excretion (and plasma steroid levels). Urinary THS excretion was low after delivery in these mothers, in normal pregnancies, and in parents of affected individuals [less than 0.05 mg/day (less than 0.08 mumol/day); P = NS]. However, 2 of the 3 heterozygous mothers who carried nonaffected fetuses excreted moderately increased amounts of THS during pregnancy, ranging from 0.15-0.26 mg/day (0.53-0.91 mumol/day), significantly higher than normal (P less than 0.01). Although urinary THS excretion in these mothers was similar to that in 2 mothers with affected fetuses early in pregnancy, urinary THS excretion was higher in mothers with affected compared to those with nonaffected fetuses after the first trimester (P less than 0.01). AF THS and 11-deoxycortisol concentrations were markedly elevated in pregnancies with affected fetuses (P less than 0.01), but normal in nonaffected ones. AF delta 4-androstenedione levels were high in 2 pregnancies and borderline elevated in a third. Although the AF tetrahydrocortisol and tetrahydrocortisone levels were always within the normal range, the AF THS to tetrahydrocortisol plus tetrahydrocortisone ratio was significantly elevated in all pregnancies with affected fetuses (2.8-5.5; P less than 0.01) and normal in nonaffected ones (0.48-1.2; P = NS) compared to that in 160 normal pregnancies [0.64 +/- 0.34 (+/- SD)]. AF 17-hydroxyprogesterone, testosterone, and 11-deoxycorticosterone levels were normal in all pregnancies. Maternal plasma 11-deoxycortisol and delta 4-androstenedione concentrations, determined sequentially throughout gestation, were variable and did not contribute to prenatal diagnosis. All affected infants were born hyperpigmented, 2 were large for gestational age, and the female was severely virilized. In the first week of life 2 males developed severe hypertension with seizures and adrenal insufficiency, respectively.(ABSTRACT TRUNCATED AT 400 WORDS)
孕期和/或分娩时对母体尿液及羊水(AF)进行激素检测,正确预测了7例有风险胎儿出生后11β-羟化酶缺乏先天性肾上腺皮质增生症(11β-OH缺乏型CAH)的诊断。在4例患病胎儿中,与20例相同孕周的正常妊娠相比,孕早期母体尿四氢-11-脱氧皮质醇(THS)排泄量较高[0.3 - 2.2mg/天(1.1 - 7.7μmol/天)],孕晚期进一步升高[0.5 - 3.5mg/天(1.8 - 12.3μmol/天)](P<0.01)。1例母亲接受地塞米松治疗(2mg/天,共72小时)后,尿THS排泄量大幅降低(以及血浆类固醇水平)。这些母亲产后尿THS排泄量较低,正常妊娠及患病个体的父母也是如此[<0.05mg/天(<0.08μmol/天);P =无显著差异]。然而,3例携带未患病胎儿的杂合子母亲中有2例孕期THS排泄量中度增加,范围为0.15 - 0.26mg/天(0.53 - 0.91μmol/天),显著高于正常水平(P<0.01)。尽管这些母亲孕早期尿THS排泄量与2例胎儿患病母亲相似,但孕早期后,胎儿患病母亲的尿THS排泄量高于胎儿未患病母亲(P<0.01)。患病胎儿妊娠的羊水THS和11-脱氧皮质醇浓度显著升高(P<0.01),未患病胎儿妊娠则正常。2例妊娠羊水δ4-雄烯二酮水平较高,第3例临界升高。尽管羊水四氢皮质醇和四氢可的松水平始终在正常范围内,但所有患病胎儿妊娠的羊水THS与四氢皮质醇加四氢可的松的比值显著升高(2.8 - 5.5;P<0.01),未患病胎儿妊娠正常(0.48 - 1.2;P =无显著差异),与160例正常妊娠相比[0.64±0.34(±标准差)]。所有妊娠的羊水17-羟孕酮、睾酮和11-脱氧皮质酮水平均正常。整个孕期连续测定的母体血浆11-脱氧皮质醇和δ4-雄烯二酮浓度变化不定,无助于产前诊断。所有患病婴儿出生时均有色素沉着,2例大于孕周,女性严重男性化。出生后第一周,2例男性分别出现严重高血压伴惊厥和肾上腺功能不全。(摘要截选至400字)